An Integrated Gene Regulatory Element for Tumor-specific Targeting Therapy

doi:10.13560/j.cnki.biotech.bull.1985.2015.10.036

Abstract

Abstract: The key for a successful tumor-specific gene therapy is to regulate the therapeutic gene specifically and efficiently expressing in tumor cells. By the construction of an embedded expression regulatory element, a high efficiency as well as tumor-specific expression of target genes in tumor cells was achieved by integrated regulation at transcriptional, post-transcriptional and translational levels simultaneously. It was shown that the integrated gene regulatory element improved expressional specificities in prostate cancer cell line LNCaP up to 420% and 480% using enhanced green fluorescent protein（EGFP）and luciferase as reporter gene respectively in vitro. By survival assay in vitro, LNCaP cell survival was specifically suppressed by HSV-1 TK expression under the control of this regulator. These results confirmed that this element could be applied in tumor-specific targeting therapy.

Key words: tumor-specific targeting therapy, embedded expression regulatory element, EGFP, HSV-1 TK, prostate cancer

Zhou Peijie, Gao Weiqiang, Fang Yuxiang. An Integrated Gene Regulatory Element for Tumor-specific Targeting Therapy[J]. Biotechnology Bulletin, 2015, 31(10): 255-262.

References

[1]Lie-A-Ling M, Bakker CT, Deurholt T, et al. Selection of tumour specific promoters for adenoviral gene therapy of cholangiocarcinoma[J]. J Hepatol, 2006, 44（1）：126-133.
[2]Foka P, Pourchet A, Hernandez AR, et al. Novel tumour-specific promoters for transcriptional targeting of hepatocellular carcinoma by herpes simplex virus vectors[J]. J Gene Med, 2010, 12（12）：956-967.
[3]Fang L, Shanqu L, Ping G, et al. Gene therapy with RNAi targeting UHRF1 driven by tumor-specific promoter inhibits tumor growth and enhances the sensitivity of chemotherapeutic drug in breast cancer in vitro and in vivo[J]. Cancer Chemother Pharmacol, 2012, 69（4）：1079-1087.
[4]Lukowski SW, Rothnagel JA, Trezise AE. CFTR mRNA expression is regulated by an upstream open reading frame and RNA secondary structure in its 5' untranslated region[J]. Hum Mol Genet, 2015, 24（4）：899-912.
[5]Wolfe AL, Singh K, Zhong Y, et al. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer[J]. Nature, 2014, 513（7516）：65-70.
[6]Spilka R, Ernst C, Mehta AK, et al. Eukaryotic translation initiation factors in cancer development and progression[J]. Cancer Lett, 2013, 340（1）：9-21.
[7]DeFatta RJ, Li Y, De Benedetti A. Selective killing of cancer cells based on translational control of a suicide gene[J]. Cancer Gene Ther, 2002, 9（7）：573-578.
[8]Moussavi M, Moshgabadi N, Fazli L, et al. Fibroblast growth factor and ornithine decarboxylase 5'UTRs enable preferential expression in human prostate cancer cells and in prostate tumors of PTEN（-/-）transgenic mice[J]. Cancer Gene Ther, 2012, 19（1）：19-29.
[9]Cipollini M, Landi S, Gemignani F. MicroRNA binding site polymorphisms as biomarkers in cancer management and research[J]. Pharmgenomics Pers Med, 2014, 7：173-1791.
[10]Valinezhad Orang A, Safaralizadeh R, Kazemzadeh-Bavili M. Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation[J]. Int J Genomics, 2014：970607.
[11]Mazzacurati L, Marzulli M, Reinhart B, et al. Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV[J]. Mol Ther, 2015, 23（1）：99-107.
[12]Li JM, Kao KC, Li LF, et al. MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells[J]. Virol J, 2013, 10：241.
[13]Lai YH, Lin CC, Chen SH, et al. Tumor-specific suicide gene therapy for hepatocellular carcinoma by transcriptionally targeted retroviral replicating vectors[J]. Gene Ther, 2015, 22（2）：155-162.
[14]Habibie, Yokoyama S, Abdelhamed S, et al. Survivin suppression through STAT3/β-catenin is essential for resveratrol-induced melanoma apoptosis[J]. Int J Oncol, 2014, 45（2）：895-901.
[15]Kogo R, How C, Chaudary N, et al. The microRNA-218~Survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer[J]. Oncotarget, 2015, 6（2）：1090-1100.
[16]Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer[J]. N Engl J Med, 2004, 351（27）：2817-2826.
[17]Hynes NE, Stoelzle T. Key signalling nodes in mammary gland development and cancer：Myc[J]. Breast Cancer Res, 2009, 11（5）：210.
[18]Meijer TW, Kaanders JH, Span PN, et al. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy[J]. Clin Cancer Res, 2012, 18（20）：5585-5594.
[19]Shi Y, Frost P, Hoang B, et al. MNK kinases facilitate c-myc IRES activity in rapamycin -treated multiple myeloma cells[J]. Oncogene, 2013, 32（2）：190-197.
[20]Lang KJ, Kappel A, Goodall GJ. Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia[J]. Mol Biol Cell, 2002, 13（5）：1792-1801.
[21]Sujobert P, Bardet V, Cornillet-Lefebvre P, et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia[J]. Blood, 2005, 106（3）：1063-1066.
[22]Fang Y, Xue JL, Shen Q, et al. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma[J]. Hepatology, 2012, 55（6）：1852-1862.